This press release from Atossa Therapeutics discusses positive developments related to their (Z)-endoxifen program, specifically focusing on the safety, tolerability, and efficacy of (Z)-endoxifen as a breast cancer prevention and treatment agent. The company also highlights potential indications they may pursue for (Z)-endoxifen, the expected design and enrollment of trials, and the market opportunities for the product. Forward-looking statements in the release address regulatory approval, patent coverage, clinical trial progress, and financial performance, among other factors. Atossa emphasizes the importance of their strategy in pursuing a metastatic indication for (Z)-endoxifen and the potential implications for future growth in the biopharmaceuticals sector, particularly in oncology.
Read more from finance.yahoo.com
